" class="no-js "lang="en-US"> Christian Kjellman - Medtech Alert
Wednesday, April 16, 2025
Christian Kjellman

Christian Kjellman

About Christian Kjellman

Christian joined Hansa Biopharma in 2008 after serving at BioInvent AB as Senior Scientist focusing on novel target evaluation and antibody technology. Prior to that, he functioned as Head of Research at the biopharmaceutical development company Cartela AB, mainly focusing on novel drug target evaluation. He has extensive research experience in cell- and molecular biology and as an Assistant Professor in Molecular Genetics at Lund University. Christian holds a M.Sc. in Chemical Biology and a Ph.D. in Tumour Immunology from Lund University.

Related Story

Hansa Biopharma Announces First Patient Treated in the Post-authorization Efficacy Study (PAES) of Idefirix® (Imlifidase) in Highly Sensitized Kidney Transplant Patients

July 11 2022

Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, […]